Expression of CD20 after viral reactivation renders HIV-reservoir cells susceptible to Rituximab
| Autor: | Serra-Peinado, Carla, Grau-Expósito, Judith, Luque-Ballesteros, Laura, Astorga-Gamaza, Antonio, Navarro, Jordi, Gallego-Rodriguez, Jenny, Martín Castillo, Mario, Curran, Adrian, Burgos, Joaquín, Ribera, Esteban, Raventós, Berta, Willekens, Rein, Torrella Domingo, Adriana, Planas, Bibiana, Badía, Rosa, García, Felipe, Castellvi, Josep, Genescà Ferrer, Meritxell, Falcó, Vicenç, Buzón, Maria José, Universitat Autònoma de Barcelona |
|---|---|
| Přispěvatelé: | [Serra-Peinado C, Grau-Expósito J, Luque-Ballesteros L, Astorga-Gamaza A, Navarro J, Gallego-Rodriguez J, Martin M, Curran A, Burgos J, Ribera E, Raventós B, Willekens R, Torrella A, Planas B, Badía R, Genescà M, Falcó V, Buzon MJ] Servei de Malalties Infeccioses, Hospital Universitari Vall d’Hebron, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR). Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain. [Castellví J] Servei de Patologia, Hospital Universitari Vall d’Hebron. Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus |
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
CD4-Positive T-Lymphocytes General Physics and Astronomy HIV Infections 02 engineering and technology Lymphocyte Activation hemic and lymphatic diseases Virus latency lcsh:Science Lymph node CD20 Multidisciplinary biology Amino Acids Peptides and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies Monoclonal::Antibodies Monoclonal Murine-Derived::Rituximab [CHEMICALS AND DRUGS] 021001 nanoscience & nanotechnology Flow Cytometry 3. Good health Virus Latency medicine.anatomical_structure Cell killing Cèl·lules T RNA Viral Rituximab 0210 nano-technology Cell activation Infection medicine.drug Anti-HIV Agents Science General Biochemistry Genetics and Molecular Biology Article 03 medical and health sciences Viral reservoirs Antigen enfermedades del sistema inmune::síndromes de inmunodeficiencia::infecciones por VIH [ENFERMEDADES] medicine Humans Immunologic Factors Hemic and Immune Systems::Hemic and Immune Systems::Immune System::Leukocytes::Leukocytes Mononuclear::Lymphocytes::T-Lymphocytes::CD4-Positive T-Lymphocytes [ANATOMY] General Chemistry Translational research medicine.disease Antigens CD20 Immune System Diseases::Immunologic Deficiency Syndromes::HIV Infections [DISEASES] sistemas sanguíneo e inmunológico::sistemas sanguíneo e inmunológico::sistema inmunológico::leucocitos::leucocitos mononucleares::linfocitos::linfocitos T::linfocitos T CD4-positivos [ANATOMÍA] 030104 developmental biology aminoácidos péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales::anticuerpos monoclonales de origen murino::rituximab [COMPUESTOS QUÍMICOS Y DROGAS] Immunology biology.protein HIV-1 Leukocytes Mononuclear lcsh:Q Infeccions per VIH Virus Activation Lymph Nodes Immunologic Memory Ex vivo |
| Zdroj: | Nature Communications Nature Communications, Vol 10, Iss 1, Pp 1-15 (2019) Dipòsit Digital de Documents de la UAB Universitat Autònoma de Barcelona Scientia |
| ISSN: | 2041-1723 |
| Popis: | The identification of exclusive markers to target HIV-reservoir cells will represent a significant advance in the search for therapies to cure HIV. Here, we identify the B lymphocyte antigen CD20 as a marker for HIV-infected cells in vitro and in vivo. The CD20 molecule is dimly expressed in a subpopulation of CD4-positive (CD4+) T lymphocytes from blood, with high levels of cell activation and heterogeneous memory phenotypes. In lymph node samples from infected patients, CD20 is present in productively HIV-infected cells, and ex vivo viral infection selectively upregulates the expression of CD20 during early infection. In samples from patients on antiretroviral therapy (ART) this subpopulation is significantly enriched in HIV transcripts, and the anti-CD20 monoclonal antibody Rituximab induces cell killing, which reduces the pool of HIV-expressing cells when combined with latency reversal agents. We provide a tool for targeting this active HIV-reservoir after viral reactivation in patients while on ART. Here, the authors identify B lymphocyte antigen CD20 as a marker for HIV-infected T cells and provide evidence for the potential use of anti-CD20 antibodies in combination with latency reversing agents for depletion of viral reactivated CD4 T cells in patients on antiretroviral therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|